Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.
作者信息
Rasche Adrianne, Mason Emily F, Strickland Stephen A, Byrne Michael, Ferrell P Brent
机构信息
Department of Nursing, Vanderbilt University Medical Center, Nashville, TN, USA.
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
出版信息
Br J Haematol. 2021 Sep;194(5):927-931. doi: 10.1111/bjh.17573. Epub 2021 Jun 7.
Abstract
摘要
相似文献
1
Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.异柠檬酸脱氢酶抑制剂驱动的分化可能类似于异基因造血细胞移植后复发的急性髓系白血病中的继发性移植物失败。
Br J Haematol. 2021 Sep;194(5):927-931. doi: 10.1111/bjh.17573. Epub 2021 Jun 7.
2
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.索拉非尼维持治疗伴 FLT3-ITD 急性髓系白血病行异基因造血干细胞移植患者：一项开放标签、多中心、随机 3 期临床试验。
Lancet Oncol. 2020 Sep;21(9):1201-1212. doi: 10.1016/S1470-2045(20)30455-1. Epub 2020 Aug 10.
3
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.接受艾伏尼布治疗后进行造血干细胞移植的异柠檬酸脱氢酶1（IDH1）突变型复发或难治性急性髓系白血病患者的预后。
Leukemia. 2021 Nov;35(11):3278-3281. doi: 10.1038/s41375-021-01229-x. Epub 2021 Mar 26.
4
Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.异柠檬酸脱氢酶抑制剂作为复发或难治性急性髓系白血病异基因干细胞移植的桥梁。
Br J Haematol. 2022 Aug;198(4):780-784. doi: 10.1111/bjh.18290. Epub 2022 May 26.
5
Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.无需供体淋巴细胞输注的持久移植物抗白血病效应——高危急性髓系白血病和骨髓增生异常综合征序贯全量供体异基因移植II期研究结果
Br J Haematol. 2018 Feb;180(3):346-355. doi: 10.1111/bjh.14980. Epub 2017 Oct 26.
6
Haploidentical unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT.亲缘半相合非亲缘异基因造血干细胞移植治疗复发/难治性急性髓系白血病：来自 EBMT 急性白血病工作组的 1578 例患者报告。
Haematologica. 2019 Mar;104(3):524-532. doi: 10.3324/haematol.2017.187450. Epub 2018 Oct 25.
7
Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation.异体造血干细胞移植后，故意供体淋巴细胞诱导的局限性急性移植物抗宿主病对于复发急性髓系白血病的长期生存至关重要。
Haematologica. 2014 Apr;99(4):751-8. doi: 10.3324/haematol.2013.089565. Epub 2013 Nov 15.
8
Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia.异基因造血干细胞移植治疗儿童 MLL 重排急性髓系白血病的疗效。
BMC Cancer. 2022 Aug 16;22(1):896. doi: 10.1186/s12885-022-09978-3.
9
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia.供者配型和身体状况影响复发或难治性急性髓系白血病患者异基因造血干细胞移植的结果。
Ann Hematol. 2012 Dec;91(12):1937-43. doi: 10.1007/s00277-012-1551-x. Epub 2012 Aug 15.
10
Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.病例报告：同种异体造血干细胞移植后伴 RUNX1-RUNX1T1 分子复发的急性髓系白血病患者采用低剂量 PD-1 阻断和阿扎胞苷进行抢先治疗。
Front Immunol. 2022 Feb 2;13:810284. doi: 10.3389/fimmu.2022.810284. eCollection 2022.
本文引用的文献
1
A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.一种用于急性髓系白血病的联合异柠檬酸脱氢酶（IDH）抑制剂和强化诱导疗法的新型分化反应。
Blood Adv. 2021 Apr 27;5(8):2279-2283. doi: 10.1182/bloodadvances.2020003685.
2
The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.基于 venetoclax 的挽救性治疗在急性髓细胞白血病造血干细胞移植后复发中的应用。
Am J Hematol. 2020 Sep;95(9):1006-1014. doi: 10.1002/ajh.25859. Epub 2020 Jun 15.
3
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.ivosidenib 治疗 IDH1 突变复发性或难治性 AML 的持久缓解。
N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.
4
Enasidenib in mutant relapsed or refractory acute myeloid leukemia.恩杂鲁胺用于治疗突变型复发或难治性急性髓系白血病。 （注：原文中药物名可能有误，推测正确药物名应该是Enasidenib为恩杂鲁胺，而这里治疗白血病的应该是Enasentinib，中文名为恩西地平 ，以下按照正确药物名给出译文）
恩西地平用于治疗突变型复发或难治性急性髓系白血病。
Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.
5
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.恩杂鲁胺诱导急性髓系白血病细胞分化以促进临床反应。
Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6.
6
Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.使用靶向突变型异柠檬酸脱氢酶1（IDH1）抑制剂AG-120治疗的急性髓系白血病伴IDH1突变患者的临床分化及分化综合征证据
Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):460-5. doi: 10.1016/j.clml.2016.04.006. Epub 2016 May 5.
Zotero 插件